COVID-19 Archives - Insights From Our Labs to Yours

Key Considerations for Medical Monitoring in CAR T Clinical Trials During the COVID-19 Pandemic and Beyond

by Labcorp Drug Developmentupdated on Tuesday, June 8, 2021Tuesday, November 3, 2020

The following blog is an adaptation of a conference presentation in September 2020 that was also re-recorded and available here Background: Medical monitoring supports the correct determination of patient eligibility for CAR T-cell therapy and plays a key role in monitoring quality patient care throughout CAR T clinical trials (see …

Understanding the voice of pediatric patients during COVID-19

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Monday, October 12, 2020

The COVID-19 pandemic forced a sudden shift in the conduct of clinical trials to ensure patients stay safe and retain access to their treatments. But how has this shift affected trials that focus on pediatric populations? To better understand the voice of pediatric patients, our team recently held an interactive, …

Adapting oncology clinical research practices and therapeutic development strategies in the covid-19 era

by Labcorp Drug Developmentupdated on Thursday, October 1, 2020Thursday, October 1, 2020

The COVID-19 outbreak that began in Wuhan, China, in December 2019 was declared a pandemic on March 11, 2020 by the World Health Organization, and has since affected almost every country around the world. Cancer patients have been significantly impacted, through both clinical practice as well as engagement and participation …

Business continuity: how robust is your patient support disaster relief plan?

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Friday, September 25, 2020

Weathering natural disasters and the COVID-19 pandemic To drive speed to therapy, reduce financial burdens and empower patient engagement, a Patient Support Services Call Center provides myriad support services that stakeholders depend upon. For pharmaceutical manufacturers, these services have gone from “nice to have” to “must-have,” driven by the growth …

Optimizing in vivo respiratory model studies

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Thursday, August 27, 2020

In vivo respiratory disease models are valuable in the identification of potential medications targeted at treating human respiratory diseases. Common respiratory diseases include lung fibrosis or the emerging COVID-19, where highly efficacious treatments are limited and where in vivo disease models can help to screen for potential new treatments. In …

Using acute respiratory disease syndrome (ARDS) in vivo models to screen for coronavirus inflammation treatment

by Labcorp Drug Developmentupdated on Thursday, August 6, 2020Wednesday, August 5, 2020

Solutions to the current COVID-19 pandemic involve preventing coronavirus infection through vaccination and treating the severe clinical symptoms of the disease, including acute respiratory distress syndrome (ARDS). Establishing in vitro screening for potential treatments, though, can be challenging, due to the limited number of appropriate research models available, and the …

Monitoring drug safety during COVID-19 – five key questions and answers

by Dr. Thomas Leigh, Executive Medical Director, Patient Safety Solutions and Adjudicationupdated on Monday, June 7, 2021Monday, July 20, 2020

Identifying, recording, and reporting adverse events is vital for ensuring drug safety, both in the pre-marketing and post-marketing settings. Today, the COVID-19 pandemic makes these activities both more critical and more challenging. Let’s consider five key safety questions and answers:

The COVID-19 road to recovery: coordinating clinical trial testing and central lab solutions

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Thursday, July 16, 2020

As COVID-19 was declared a pandemic, our Clinical Trials Testing Solutions (CTTS) witnessed a sudden influx of COVID-19 studies from both large pharmaceutical organizations and biotechs. Not only did CTTS need to accelerate the timelines for these drug development sponsors’ urgent studies, but they needed to provide patient-centric testing solutions, …

Immunogenicity studies for the coronavirus vaccines: How to stay on track and build testing capacity even during COVID-19

by Labcorp Drug Developmentupdated on Monday, June 7, 2021Friday, July 3, 2020

As the world waits for a vaccine to protect against COVID-19, the disease caused by the novel coronavirus, it will need not only scientific excellence but also business continuity excellence to keep vital research and immunogenicity studies running. Vaccine development relies on many early, nonclinical studies; some of the earliest …

COVID-19: vaccine innovation and safety at pandemic speed

by Jerome Premmereur, VP Patient Safety Solutions & Adjudicationupdated on Thursday, July 2, 2020Tuesday, June 30, 2020

Introduction Recently, I was privileged to act as the moderator for a World Drug Safety Congress webinar exploring current considerations for developing and testing COVID-19 vaccine solutions at pandemic speed. Our panel of experts included: